All subjects | GOLD 1 | GOLD 2 | GOLD 3 | GOLD 4 | |
Subjects n | 268 | 69 | 121 | 65 | 13 |
Age years | 70±8 | 67±8 | 70±8 | 72±6 | 70±8 |
Females | 15 (6) | 9 (13) | 6 (5) | 0 (0) | 0 (0) |
Body mass index kg·m−2 | 22±3 | 23±3 | 23±3 | 21±3 | 21±4 |
Current smoker at entry | 74 (28) | 20 (29) | 39 (32) | 10 (15) | 5 (38) |
Smoking index at entry pack-years | 62±30 | 63±34 | 62±30 | 64±25 | 55±22 |
Post-bronchodilator | |||||
FEV1 L | 1.75±0.67 | 2.55±0.43 | 1.76±0.41 | 1.11±0.19 | 0.70±0.14 |
FEV1 % predicted | 65±22 | 93±11 | 65±9 | 42±5 | 26±4 |
FVC % predicted | 101±19 | 118±13 | 100±14 | 90±14 | 70±20 |
FEV1/FVC | 0.51±0.13 | 0.64±0.06 | 0.53±0.08 | 0.38±0.07 | 0.31±0.07 |
Reversibility of FEV1 % | 12±10 | 6±5 | 12±8 | 17±13 | 14±11 |
Reversibility of FEV1 mL | 146±105 | 124±88 | 162±101 | 153±127 | 86±66 |
Chronic bronchitis | 29 (11) | 2 (3) | 15 (12) | 11 (17) | 1 (8) |
MRC dyspnoea score ≥2 | 224 (84) | 47 (68) | 102 (84) | 62 (95) | 13 (100) |
SGRQ total score | 32±18 | 23±14 | 30±17 | 41±16 | 51±14 |
Blood neutrophil count cells·mm−3 | 3519±1113 | 3597±1220 | 3421±1155 | 3580±975 | 3713±733 |
Blood eosinophil count cells·mm−3 | 198±134 | 185±130 | 211±137 | 184±128 | 218±152 |
Blood haemoglobin g·dL−1 | 14±1 | 14±1 | 14±1 | 14±1 | 14±1 |
Serum IgE IU·mL−1 | 213±569 | 278±764 | 251±606 | 88±106 | 140±158 |
Any cardiovascular disease | 60 (22) | 12 (17) | 27 (22) | 17 (26) | 4 (31) |
Ischaemic heart disease | 19 (7) | 5 (7) | 9 (7) | 5 (8) | 0 (0) |
Diabetes | 12 (4) | 3 (4) | 7 (6) | 2 (3) | 0 (0) |
Data are presented as mean±sd or n (%), unless otherwise stated. GOLD: Global Initiative for Chronic Obstructive Lung Disease; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; MRC: Medical Research Council; SGRQ: St George’s Respiratory Questionnaire.